PT  - JOURNAL ARTICLE
AU  - Bennett, James Thomas
AU  - Shirley, Sarah
AU  - Murray, Patricia
AU  - Wilm, Bettina
AU  - Field, Mark
TI  - Kidney Protection During Surgery on the Thoracoabdominal Aorta: A Systematic Review
AID  - 10.1101/2024.06.25.24309413
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.06.25.24309413
4099  - http://medrxiv.org/content/early/2024/09/02/2024.06.25.24309413.short
4100  - http://medrxiv.org/content/early/2024/09/02/2024.06.25.24309413.full
AB  - Background Acute kidney injury (AKI) is a common complication of surgery to repair the thoracoabdominal aorta, and is associated with risks of dialysis and early mortality. Renal ischaemia, initiated by clamping of the suprarenal aorta, is a major cause. Consequently, perfusion techniques are commonly used to sustain renal blood flow or facilitate hypothermic kidney preservation during surgery. This systematic review provides a comprehensive assessment of renal and mortality outcomes by perfusion techniques, to evaluate their ability to provide effective kidney protection.Methods & Results Searches of PubMed, Web of Science, ClinicalTrials.gov and ClinicalTrialsRegister.EU were conducted to identify relevant studies published from 1995 to 2024. Included studies were quality assessed, and data were extracted by perfusion techniques. Outcomes of the highest quality studies were used to synthesise a narrative discussion.Forty-five studies were included in our analysis, featuring three extracorporeal strategies: Left heart bypass (LHB; n=24), cardiopulmonary bypass with deep hypothermic circulatory arrest (DHCA; n=19), and partial cardiopulmonary bypass (pCPB; n=12). Three categories of selective renal perfusion strategy were identified: Warm blood, cold blood and cold crystalloid. Our analysis identified operative mortality as 0-23.4% following LHB, 2.2-12.5% following DHCA and 0-42.1% following pCPB. The incidence of renal replacement therapy was 0-40.0% following LHB, 0-15.0% following DHCA and 0-22.2% following pCPB.Conclusions Strong evidence supports the use of distal aortic perfusion (DAP) with LHB or pCPB, to reduce the risks of dialysis and operative mortality associated with aortic cross clamping. Furthermore, when DAP cannot prevent kidney ischaemia, adjunctive perfusion of the renal arteries with cold histidine-tryptophan-ketoglutarate (HTK) can reduce the risk of AKI. However, no professional guidance on the management of HTK exists, and rates of AKI remain high despite its use. Selective renal perfusion with warm blood is identified as a risk factor for AKI and operative mortality. DHCA is associated with low rates of AKI, warranting further prospective investigation. Finally, intravascular haemolysis and myoglobinaemia are acknowledged as important risk factors that require urgent research to address the problem of AKI.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.crd.york.ac.uk/PROSPEROFILES/166428_PROTOCOL_20200122.pdf Funding StatementThis study did not receive any external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.AKIAcute kidney injuryAKINAcute kidney injury networkATNAcute tubular necrosisATPAdenosine TriphosphateCPBCardiopulmonary bypassDAPDistal aortic perfusionDHCADeep hypothermic circulatory arrestECCExtracorporeal circulationEUEuropean UnionHLMHeart lung machineIRIIschaemia-reperfusion injuryKDIGOKidney disease improving global outcomesLHBLeft heart bypasspCPBPartial cardiopulmonary bypassPOSProspective observational studyPRISMAPreferred reporting items for systematic reviews and meta-analysesQOLQuality of LifeRCTRandomised controlled trialRIFLERisk, Injury, Failure, Loss, End Stage Renal DiseaseROBRisk of biasROSRetrospective observational studyRRTRenal replacement therapiesSACCSimple aortic cross clampingSRPSelective renal perfusionSWiMSynthesis without meta-analysisTAAThoracoabdominal aorta